Leukemia Research
Volume 27, Issue 5 , Pages 393-396 , May 2003

The expression of PRAME in chronic lymphoproliferative disorders

  • Rodrigo Proto-Siqueira

      Affiliations

    • Department of Clinical Medicine and Center of Cell-based Therapy, Faculty of Medicine of Ribeirão Preto, Hemocentro de Ribeirao Preto, Rua Tenente Catao Roxo, 2501 Ribeirao Preto, 14051-140 SP Brazil
    • ,
  • Roberto Passetto Falcão

      Affiliations

    • Department of Clinical Medicine and Center of Cell-based Therapy, Faculty of Medicine of Ribeirão Preto, Hemocentro de Ribeirao Preto, Rua Tenente Catao Roxo, 2501 Ribeirao Preto, 14051-140 SP Brazil
    • ,
  • Carmino Antonio de Souza

      Affiliations

    • Department of Internal Medicine, Faculty of Medicine State University of Campinas, Campinas, Brazil
    • ,
  • Sebastião José Ismael

      Affiliations

    • Department of Clinical Medicine and Center of Cell-based Therapy, Faculty of Medicine of Ribeirão Preto, Hemocentro de Ribeirao Preto, Rua Tenente Catao Roxo, 2501 Ribeirao Preto, 14051-140 SP Brazil
    • ,
  • Marco Antonio Zago

      Affiliations

    • Department of Clinical Medicine and Center of Cell-based Therapy, Faculty of Medicine of Ribeirão Preto, Hemocentro de Ribeirao Preto, Rua Tenente Catao Roxo, 2501 Ribeirao Preto, 14051-140 SP Brazil
    • Corresponding Author InformationCorresponding author. Tel.: +55-16-3963-9361; fax: +55-16-3963-9309.

Received 10 April 2002 ,Accepted 4 September 2002.

References 

  1. Matsushita M, Ikeda H, Kizaki M, Okamoto S, Ogasawara M, Ikeda Y, et al.  Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br. J. Haematol. 2001;112:916–926
  2. Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, De Smet C, et al.  Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6:199–208
  3. van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, et al.  PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br. J. Haematol. 1998;102:1376–1379
  4. Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U, et al.  Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp. Hematol. 2000;28:1413–1422
  5. van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, et al.  Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood. 1999;94:1156–1164
  6. Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, et al.  Efficient identification of novel HLA-A(∗)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 2001;193:73–88
  7. Lethé B, van der Bruggen P, Brasseur F, Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res. 1997;7(Suppl. 2):S83–S88
  8. Watari K, Tojo A, Nagamura-Inoue T, Nagamura F, Takeshita A, Fukushima T, et al.  Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. FEBS Lett. 2000;466:367–371
  9. De S, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 1999;19:7327–7335
  10. Sigalotti L, Coral S, Altomonte M, Natali L, Gaudino G, Cacciotti P, et al.  Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br. J. Cancer. 2002;86:979–982
  11. Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet. Cytogenet. 2002;133:118–230

PII: S0145-2126(02)00217-5

doi: 10.1016/S0145-2126(02)00217-5

Leukemia Research
Volume 27, Issue 5 , Pages 393-396 , May 2003

Article Tools

* Image Usage & Resolution